Medicine and Dentistry
Adalimumab
11%
Azathioprine
15%
Biological Product
23%
Biological Therapy
31%
Biopsy
9%
Birth Outcomes
15%
Bland-Altman Plot
10%
Colitis
11%
Collagenous Colitis
15%
Colonoscopy
15%
Colorectal Cancer
15%
Combination Therapy
14%
Consultation
10%
Crohn's Disease
45%
Diseases
34%
Drug Dose Intensification
15%
Drug Therapy
9%
Dysplasia
15%
Endoscopy
27%
Esophagus Mucosa
15%
Faecal Calprotectin
15%
Fistula
13%
Gastroesophageal Reflux
15%
Health Care Cost
15%
Hidradenitis Suppurativa
8%
Inflammatory Bowel Disease
100%
Inflammatory Disorder
31%
Infliximab
15%
Kappa Statistics
10%
Maintenance Therapy
24%
Outpatient
17%
Patient Care
15%
Patient with Crohn's Disease
28%
Patient with Inflammatory Bowel Disease
38%
Patient with Ulcerative Colitis
19%
Personalized Medicine
46%
Pharmacokinetics
15%
Placebo
15%
Premedication
15%
Prognostic Factor
31%
Prospective Cohort Study
15%
Psoriasis
8%
Randomized Controlled Trial
15%
Spondylarthritis
8%
Symptom
33%
TNF Inhibitor
21%
Treatment Response
12%
Tumor Necrosis Factor
34%
Ulcerative Colitis
36%
Uveitis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
27%
Azathioprine
15%
Biological Product
15%
Combination Therapy
13%
Crohn's Disease
40%
Disease
19%
Drug Concentration
5%
Fistula
13%
Immunosuppressive Agent
7%
Infection
19%
Inflammatory Bowel Disease
48%
Infliximab
62%
Iron Deficiency
15%
Irritable Colon
15%
Mercaptopurine
11%
Rectum Hemorrhage
5%
Remission
5%
Spondylarthritis
5%
Standardized Incidence Ratio
15%
Suppurative Hidradenitis
5%
Symptom
7%
Tumor Necrosis Factor
21%
Tumor Necrosis Factor Inhibitor
11%
Ulcerative Colitis
22%
Uveitis
5%
Keyphrases
6-mercaptopurine (6-MP)
15%
Anti-infliximab Antibodies
5%
Anti-TNF Treatment
15%
Anti-tumor Necrosis Factor Agents
11%
Attached mucosa
7%
Basal Layer
7%
Biologic Therapy
15%
Candidate Gene Expression
5%
Clinical Markers
7%
Clinical Remission
6%
Colonoscopy Surveillance
15%
Complex Fistula
7%
Dose Intensification
15%
Drug Administration
5%
Harvey-Bradshaw Index
9%
Hidradenitis Suppurativa
5%
Histopathological Findings
7%
Inflammatory Bowel Disease
15%
Infliximab
15%
Infliximab Failure
5%
Lactating Women
5%
Lifestyle Recommendations
15%
Macroscopic Findings
15%
Maternal Milk
10%
Maximum Permissible Concentration
5%
Mercaptopurine
5%
Microscopic Appearance
15%
Non-academic Hospital
12%
Normal Birth
5%
Patient Phenotype
15%
Population-based
15%
Premedication
15%
Primary Response
7%
Pro-inflammatory Molecules
5%
SCCAI
6%
Short Health Scale
15%
Similar Curves
5%
Standardized Incidence Ratio
15%
Thiopurines
5%
Treatment Discontinuation
7%
Treatment during Pregnancy
5%